pharmaphorum

NICE backs NHS use of Novartis' cholesterol drug Leqvio

Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE. The PCSK9-targeting oligonucleotide ...

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029

Novartis AG (NYSE:NVS) ranks among the best slow growth stocks to invest in. Following meetings with Novartis AG (NYSE:NVS)’s ...
Pharmabiz

Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis announced positive results from V-DIFFERENCE, a phase IV study evaluating Leqvio (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy ...
Daily Express

High cholesterol jab could 'transform' heart care

12:54, Sun, Aug 31, 2025 Updated: 12:57, Sun, Aug 31, 2025 A twice-yearly jab that combats cholesterol could revolutionise heart care, according to its creator. The drug, Leqvio, also known as ...
Finanznachrichten

Novartis Pharma AG: Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain 1 85% ...
manilatimes

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo plus LLT1 Basel, August 30, 2025 - Novartis today announced positive results ...
Yahoo Finance

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. Novartis Pharmaceuticals Canada Inc.
WebMD

Leqvio for Hyperlipidemia

Sometimes diet and exercise are not enough to lower cholesterol levels. Many different medicine options exist, including Leqvio, which can be used alone or with other medicines to help people reach ...
AOL

Which Medicare part covers Leqvio?

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...
WebMD

Leqvio: New Injectable Option for Lowering Bad Cholesterol Without Statins

What Is Leqvio, and Why Does It Matter? Leqvio (inclisiran) is a prescription injection that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol, which is a ...
Medindia

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as ...
Pharm Exec

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Leqvio's label update allows its use as a first-line monotherapy for LDL-C reduction in hypercholesterolemia, reflecting strong PCSK9-targeting evidence. The update addresses an unmet need, as many ...